On May 10, 2021, Inovio Pharma announced positive safety, tolerability and immunogenicity data from its placebo-controlled and blinded Phase 2 segment of its Phase 2/3 clinical trial in the U.S., called INNOVATE (INOVIO INO-4800 Vaccine Trial for Efficacy), evaluating INO-4800, its DNA vaccine candidate for COVID-19.

Preliminary results showed in a larger population that INO-4800 was generally safe, well-tolerated and immunogenic in all studied age groups. The trial was funded by the Department of Defense.